Content repurposed with permission from: type1better.com Despite best efforts to keep a child’s blood glucose within target, severe hypoglycemic episodes can happen, and it’s best to be prepared for the unpredictable. The […]
A significant part of JDRF Canada funding goes towards supporting cure-based research for type 1 diabetes (T1D). One such pathway is via stem cell replacement therapies that replace the beta […]
Throughout June more than 40 communities gathered across Canada to raise funds for type 1 diabetes research. The Sun Life Walk to Cure Diabetes for JDRF is the largest fundraising […]
A 2013-2016 JDRF-funded study showed that the use of a continuous glucose monitor (CGM) during pregnancy for people with type 1 diabetes (T1D) results in healthier pregnancies and babies. The […]
The American Diabetes Assocation’s 83rd Scientific Sessions were held from June 23- 26th. This annual conference brings together researchers and scientists to both present and learn about the latest in […]
What is Glucagon? Glucagon is a hormone that helps the liver release glucose to raise blood glucose levels. It can be administered through injection, auto-injection pen or nasal spray. Glucagon […]
JDRF Canada, in collaboration with CIHR, is thrilled to announce the recipients of the CIHR-JDRF Type 1 Diabetes Screening Research Consortium. This $12 million grant will develop a single nationally […]
A large area of cure-based T1D research is investigating stem cell-based therapy. The goal of this approach is to use stem cells as a renewable source of insulin-producing cells which, […]
The name Garfinkle is synonymous with JDRF Canada. Over 50 years ago, in 1971 and 1973 respectively, Krayna Golfman and Mitch Garfinkle saw their sons, David and Jimmy diagnosed with […]
Low blood sugar, called hypoglycemia, is a real fear for people with type 1 diabetes (T1D). Although there are rescue treatments for it, such as injectable or nasal glucagon (Baqsimi), there are currently no preventive therapies available. Canadian company Zucara Therapeutics, however, may have an answer.
On May 23, 2023 the U.S. Food and Drug Administration (FDA) cleared the iLet® Insulin-Only Bionic Pancreas System for people 6 years of age and older with type 1 diabetes […]
JDRF provides seed funding for highly innovative research with significant potential to accelerate the most promising type 1 diabetes (T1D) research in both cures and approaches to improve disease management. […]
